Long
SOLY falling despite strong clinical trial results
Investors bought the hype surrounding SOLY's clinical trial results, and today they sold the news. SOLY fell nearly 14% despite better-than-expected results in its cellulite treatment trial.
Looking at the volume profile, I think SOLY may continue to fall to the 14.00-14.50 range, and then rebound upward from there. I wouldn't enter any earlier than that.
Looking at the volume profile, I think SOLY may continue to fall to the 14.00-14.50 range, and then rebound upward from there. I wouldn't enter any earlier than that.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.